Survival by treatment regimen. The survival for the 309 randomized patients did not differ by postremission treatment arm (log-rank test, P = .89). The 5-year survival proportions were 44% (95% CI, 36%-52%) for those assigned to receive 3 courses of HiDAC (solid line) and 46% (95% CI, 38%-54%) for those assigned to receive sequential MCT (dotted line).